Ricardo Alvarez, Medical Director of the Breast Cancer Center & Director of Cancer Research, Cancer Treatment Centers of America (CTCA), Atlanta, GA, US, talks to touchONCOLOGY about the mutational landscape of metastatic cancers discovered from prospective clinical sequencing at a community practice cancer programme and the findings from the data he presented at ESMO 2018 in Munich, Germany. Dr Alvarez also discusses which type of patients are ideal candidates for next generation sequencing, and he highlights some of the limitations of precision medicine. Finally, Dr Alvarez gives us his throughs on the future of precision medicine and how this translate to clinical practice.
1. What proportion of cancer patients in your institution are receiving drugs matched to mutations in their tumours? (0:11)
2. Could you tell us a little about the data you are presenting from community practices? (0:48)
3. Which tumours are most amenable to this approach? (1:59)
4. What are the limitations of this approach? (2:43)
5. By how much do you expect the proportion of cancer patients receiving matched treatment to rise in the coming years? (3:42)
Speaker disclosures: Ricardo Alvarez has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and trastuzumab deruxtecan + pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!